Activation of STAT3 by the c-Fes Protein-tyrosine Kinase*

Kristie L. NelsonDagger , Jim A. RogersDagger , Tammy L. Bowman§, Richard Jove§, and Thomas E. SmithgallDagger

From the Dagger  Eppley Institute for Research in Cancer and Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198-6805, and the § Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida 33612

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

STATs (signal transducers and activators of transcription) are transcription factors that contain SH2 domains and are activated by tyrosine phosphorylation, often in response to cytokine stimulation. Recent evidence indicates that the transforming tyrosine kinases encoded by the v-Src, v-Abl, and v-Fps oncogenes can induce STAT activation, suggesting that their normal cellular homologs may contribute to STAT activation under physiological conditions. In this report, we provide direct evidence that c-Fes, the normal human homolog of v-Fps, potently activates STAT3. Transient transfection of human 293T cells with STAT3 and Fes resulted in strong stimulation of STAT3 DNA binding activity. In contrast, only modest activation of STAT5 by Fes was observed in this system, indicative of possible selectivity. To determine whether Fes-induced STAT3 activation is dependent upon endogenous mammalian kinases, co-expression studies were also performed in Sf-9 insect cells. Fes also induced a dramatic increase in STAT3 DNA binding activity in this system, whereas no activation of STAT5 was observed. As a positive control, both STAT3 and STAT5 were shown to be activated by the Bcr-Abl tyrosine kinase in Sf-9 cells. Fes induced strong tyrosine phosphorylation of STAT3 in both expression systems, consistent with the gel-shift results. Fes and STAT3 have been independently linked to myeloid differentiation. Results presented here suggest that these proteins may cooperate to promote differentiation signaling in response to hematopoietic cytokines.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

STATs (signal transducers and activators of transcription) are a class of transcription factors with SH2 domains that are activated in response to tyrosine phosphorylation. STATs are often activated by members of the JAK family of protein-tyrosine kinases in response to cytokine stimulation. The activation mechanism involves SH2-dependent recruitment of the STATs to tyrosine-phosphorylated cytokine receptors. The STATs are then phosphorylated by receptor-associated JAKs, which induces dimerization via reciprocal SH2-phosphotyrosine interaction. The STAT dimers then enter the nucleus and bind specific DNA elements, leading to transcriptional activation. The JAK-STAT pathway is the subject of many recent comprehensive reviews (1-5).

In addition to JAKs, other classes of non-receptor protein tyrosine kinases have recently been shown to induce STAT activation. For example, STAT3 is constitutively activated in fibroblasts transformed with v-Src (6, 7). Src forms a stable complex with STAT3, suggesting that STAT3 activation may be direct (7). However, more recent work shows that JAK1 and to some extent JAK2 are activated in Src-transformed cells, suggesting that JAKs may contribute to STAT activation by Src kinases (8). Another study has shown that STATs 1 and 5 are activated in fibroblasts transformed by v-Abl (9). In this case, v-Abl was shown to form stable complexes with endogenous JAK kinases, suggesting that STAT activation by v-Abl may involve JAKs as well. Related studies with chronic myelogenous leukemia cell lines transformed by Bcr-Abl show a similar pattern of STAT activation, with some evidence for JAK involvement (10-12).

Recently, we observed that fibroblast transformation by v-Fps correlates with potent activation of endogenous STAT3 (13). This finding suggested that STAT3 may also be a substrate and effector protein for c-Fes, the normal human homolog of v-Fps (14-16). The c-Fes tyrosine kinase exhibits strong hematopoietic expression, is activated in response to multiple cytokines (17-20), and has been linked directly to the control of myeloid differentiation (21, 22). Recent studies have shown that activation of STAT3 is necessary for induction of myeloid differentiation in response to IL-6 (23, 24), one of the cytokines known to activate c-Fes (19). Taken together, these previous studies suggest that c-Fes may contribute to STAT activation under physiological conditions. In this study, we provide evidence for the activation of STAT3 by Fes in human cells as well as Sf-9 insect cells. Fes potently activated STAT3 in both systems, suggesting that STAT3 may be a direct substrate for Fes and may mediate Fes differentiation signaling in myeloid cells.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cell Lines-- 293T cells (25) were obtained from the American Type Culture Collection (ATCC) and grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum and 50 µg/ml gentamicin. Sf-9 cells were obtained from the ATCC and grown in Grace's insect cell medium supplemented with 10% fetal bovine serum and 50 µg/ml gentamicin.

Expression of Fes and STAT Proteins in 293T Cells-- The cDNAs encoding murine STAT3 and STAT5A were subcloned into the respective expression vectors pCDNA3 and pCDNA3.1(-) (Invitrogen). Construction of expression vectors for Fes and the kinase-inactive Fes mutant K590E with C-terminal FLAG epitope tags and calcium phosphate-mediated transfection of 293T cells is described elsewhere (26).

Generation of Recombinant Baculoviruses and Expression of Proteins in Sf-9 Insect Cells-- STAT3 and STAT5A cDNAs were subcloned into the baculovirus transfer vectors pVL1392 and pVL1393, respectively. The resulting constructs were used to make recombinant baculoviruses by co-transfection with BaculoGold DNA (Pharmingen) using the manufacturer's protocol. A cDNA encoding the p210 form of Bcr-Abl (generous gift of Dr. Owen Witte, Howard Hughes Medical Institute, UCLA) was used to make a recombinant baculovirus by the same procedure. Construction of baculoviruses for the expression of wild-type and kinase-defective Fes has been described elsewhere (26). Baculovirus-expressed Fes proteins carry a C-terminal FLAG epitope tag to allow for detection with the M2 monoclonal antibody. For protein expression, Sf-9 cells were grown to 50% confluence on 60-mm tissue culture plates and infected with recombinant baculoviruses for 1 h at 27 °C. The virus was replaced with fresh medium, and the cells were incubated for 48 h prior to preparation of cytosolic extracts.

Preparation of Cytosolic Extracts-- Cytosolic extracts were made following a previously published protocol (6). Briefly, culture plates of 293T or Sf-9 cells were washed twice with ice-cold PBS followed by PBS containing 1 mM sodium orthovanadate and 5 mM sodium fluoride. The cells were rinsed with hypotonic buffer (20 mM HEPES, pH 7.9, 1 mM EDTA, 1 mM EGTA, 20 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM sodium pyrophosphate, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 50 µg/ml leupeptin, and 25 µg/ml aprotinin). The cells were then lysed in hypotonic buffer containing 0.2% Triton X-100 and clarified by microcentrifugation. The protein concentration of the extract was determined using the Coomassie-plus reagent (Pierce) and stored at -80 °C.

Electrophoretic Mobility Shift Assay-- The probes used for STAT DNA binding included the sis-inducible element (SIE) (6) and the mammary gland factor element (MGFE) (27). The sequences of the SIE oligonucleotides are 5'-CTTCATTTCCCGTAAATCCCTAAAGCT-3' and 5'-AGCTTTAGGGATTTACGGGAAATGA-3'. The sequences of the MGFE oligonucleotides are 5'-AGATTTCTAGGAATTCAA-3' and 5'-GATTTGAATTCCTAGAAA-3'. Oligonucleotides (20 pmol) were annealed in 10 µl of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) by heating to 70 °C and slowly cooling to room temperature. The probes were labeled by combining 1 µl of annealed oligonucleotide with 2 µl of Labeling Mix-dATP (Pharmacia Biotech Inc.), 2 µl of [alpha -32P]dATP (10 mCi/ml; Amersham Life Science, Inc.), and 1 µl of the Klenow fragment of DNA polymerase (Life Technologies, Inc., 3.7 units/µl). The mixture was incubated at room temperature for 30 min. and the unincorporated nucleotides were removed by spermine precipitation (28). DNA binding reactions contained 40,000 cpm of labeled probe in a final volume of 20 µl and 2-6 µg of cytosolic protein extract. In the case of the cytosolic extract from Sf-9 cells, 0.5 µl of a 1.0 ml cytosolic extract from 6 × 106 cells was used in each reaction. The reactions were incubated at 30 °C for 30 min and run on 5% polyacrylamide gels in 0.25× Tris borate-EDTA buffer. Gels were fixed with 10% acetic acid, 10% methanol, rinsed with water, dried, and exposed to a storage phosphor screen. Images were visualized using a Molecular Dynamics PhosphorImager.

Immunoprecipitation and Immunoblotting-- For immunoprecipitation, clarified cytosolic extracts were incubated with 1 µg of anti-STAT3 or anti-STAT5 antibodies (Santa Cruz Biotechnology) and 20 µl of protein G-Sepharose (50% slurry; Pharmacia) for 1 h at 4 °C. The immunoprecipitates were washed three times with 1 ml of radioimmune precipitation buffer (26) followed by heating in SDS-PAGE sample buffer. For immunoblotting, cytosolic extracts or immunoprecipitated proteins were run on 8% polyacrylamide gels and transferred to PVDF membranes. The membranes were incubated for 1 hour with antibodies to Fes (M2 anti-FLAG antibody; Eastman-Kodak Co.), phosphotyrosine (PY20; Transduction Laboratories), STAT3 (Santa Cruz) or STAT5 (Transduction Laboratories) at 1 µg/ml in Tris-buffered saline containing 0.05% Tween-20 (TBST)1 and 1.5% bovine serum albumin. The membranes were then washed in TBST and probed with a secondary antibody-alkaline phosphatase conjugate in TBST-bovine serum albumin at the dilution recommended by the manufacturer (Southern Biotechnology Associates). Following further washing with TBST, the immunoreactive proteins were visualized colorimetrically using the alkaline phosphatase substrate NBT/BCIP.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Activation of STAT3 by c-Fes in 293T Cells-- Recently we observed that endogenous STAT3 is constitutively activated in fibroblasts transformed by v-Fps, a retroviral homolog of c-Fes (13). Given the relationships of c-Fes and STAT3 to myeloid differentiation (21, 23, 24, 29), we decided to investigate whether STAT3 or other STAT factors represent possible Fes substrates and effector molecules. To determine whether STAT3 is activated by Fes, the two proteins were expressed either alone or together in human 293T cells. Cytosolic extracts were prepared and tested for the presence of active STAT3 in a gel-shift assay with an SIE probe. As shown in Fig. 1, extracts from cells co-transfected with both Fes and STAT3 produced a dramatic shift in SIE mobility, indicative of STAT3 activation. Addition of a 100-fold molar excess of unlabeled SIE completely blocked complex formation, providing evidence of probe specificity.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 1.   Activation of STAT3 by Fes in 293T cells. Human 293T cells were transfected with STAT3, Fes, or a kinase-inactive Fes mutant (Fes-KE) either alone or in the combinations shown. Cytosolic extracts were prepared and tested for the presence of active STAT3 by gel-shift analysis with an SIE probe. Control lanes include incubation of the probe in the absence of extract (SIE) and gel-shift assays of untransfected cell extracts (293T). Duplicate gel-shift assays were conducted in the presence of a 100-fold excess of unlabeled SIE to demonstrate probe specificity (COMP). The shifted complex of activated STAT3 and the SIE probe is denoted by the arrow.

To demonstrate that the activation of STAT3 requires the tyrosine kinase activity of c-Fes, 293T cells were co-transfected with STAT3 and a kinase-defective Fes mutant (Fes-K590E) (30). As shown in Fig. 1, co-expression with the kinase-defective protein produced only low background levels of STAT3·SIE complexes equivalent to those observed when STAT3 was expressed alone. This result shows that stimulation of STAT3 DNA binding activity requires an active Fes kinase domain and is consistent with STAT3 tyrosine phosphorylation data shown below. We also investigated the requirements for other structural features of c-Fes in STAT3 activation using a series of Fes deletion and autophosphorylation site mutants. Co-expression of STAT3 with a Fes mutant lacking the unique N-terminal domain (amino acids 1-450) (26) activated STAT3 to the same extent as wild-type c-Fes (data not shown). This result suggests that the Fes N-terminal region, while involved in the recruitment of some Fes substrates (31, 32) is dispensable for interaction with STAT3. However, deletion of the Fes SH2 domain or mutagenesis of Tyr-713, the major Fes autophosphorylation site (26, 30), greatly diminished STAT3 activation (data not shown). The latter two mutations reduce Fes tyrosine kinase activity in vitro (30), which may account for their reduced efficiency of STAT3 activation.

To determine whether Fes exhibits a preference for STAT3, Fes was co-expressed with STAT5 in 293T cells. Cell lysates were tested for the presence of activated STAT5 using the MGFE as a probe. As shown in Fig. 2, Fes stimulated STAT5 DNA binding activity. However, activation of STAT5 by Fes was modest in comparison to STAT3 (3-fold for STAT5 versus 35-fold for STAT3 relative to background levels observed with the kinase-inactive Fes mutant). These results suggest that Fes preferentially activates STAT3 over STAT5 in this system. In addition, work with Sf-9 insect cells described below suggests that STAT5 activation by Fes in mammalian cells may be indirect, possibly involving an intermediate tyrosine kinase.


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 2.   Activation of STAT5 by Fes in 293T cells. Human 293T cells were transfected with STAT5A, Fes, or a kinase-inactive Fes mutant (Fes-KE) either alone or in the combinations shown. Cytosolic extracts were prepared and tested for the presence of active STAT5 by gel-shift analysis with an MGFE probe. Control lanes include incubation of the probe in the absence of extract (MGFE) and gel-shift assays of untransfected cell extracts (293T). Duplicate gel-shift assays were conducted in the presence of a 100-fold excess of unlabeled MGFE to demonstrate probe specificity (COMP). The shifted STAT5-MGFE complex is denoted by the arrow.

Fes Induces Tyrosine Phosphorylation of STAT3 and STAT5 in 293T Cells-- Tyrosine phosphorylation is required to induce STAT factor dimerization, nuclear localization, and DNA binding (1, 2, 5). To determine whether stimulation of STAT3 DNA binding activity by Fes correlated with tyrosine phosphorylation, STAT3 was immunoprecipitated from transfected 293T cell lysates and analyzed by immunoblotting with the anti-phosphotyrosine antibody, PY20. As shown in Fig. 3, STAT3 was strongly phosphorylated on tyrosine following co-expression with Fes, consistent with the positive gel-shift result. In contrast, control STAT3 immunoprecipitates from cells expressing STAT3 alone or in the presence of the kinase-inactive Fes mutant were devoid of tyrosine phosphorylation. Control immunoblots show that equivalent amounts of STAT3 were immunoprecipitated in each case and that equivalent levels of the wild-type and kinase-inactive Fes proteins were expressed (Fig. 3). These results suggest that STAT3 is either a direct substrate for Fes, that Fes activates an endogenous tyrosine kinase that in turn phosphorylates STAT3, or both. Data described below with Sf-9 insect cells strongly support the hypothesis that STAT3 is a direct substrate for Fes. However, the contribution of an endogenous tyrosine kinase in mammalian cells cannot be ruled out. Whatever the specific mechanism, these results demonstrate that c-Fes can strongly activate STAT3 in a human cell context. This finding is particularly interesting in light of recent data directly implicating STAT3 in myeloid differentiation.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Fes induces tyrosine phosphorylation of STAT3 and STAT5 in 293T cells. Human 293T cells were transfected with STAT3, STAT5, Fes, or a kinase-inactive Fes mutant (Fes-KE) either alone or in the combinations shown. Untransfected cells were also included as an additional negative control (293T). Cytosolic extracts were prepared and incubated with antibodies to either STAT3 or STAT5. Immune complexes were precipitated with protein G-Sepharose and immunoblotted with antibodies to phosphotyrosine (PY20, top). To verify equivalent recovery of STAT proteins, aliquots of the immunoprecipitates were also blotted with the STAT antibodies (center). To verify the expression of Fes and Fes-KE, the cytosolic extracts were immunoblotted with the anti-FLAG antibody, M2 (bottom).

We also investigated whether Fes could induce tyrosine phosphorylation of STAT5 in 293T cells using the same approach. As shown in Fig. 3, STAT5 immunoprecipitates from 293T cells co-transfected with STAT5 and Fes showed evidence of tyrosine phosphorylation. This finding is in good agreement with the positive gel-shift result shown in Fig. 2. As with STAT3, tyrosine phosphorylation was not observed when STAT5 was expressed alone or in the presence of the kinase-inactive Fes mutant, K590E. Control blots show equivalent levels of STAT5 in the immunoprecipitates and equal levels of wild-type and kinase-defective Fes in the cell lysates (Fig. 3). These results show that Fes can induce the tyrosine phosphorylation and activation of STAT5 in mammalian cells. Recent studies suggest that STAT5, like STAT3, may contribute to hematopoietic differentiation (see Discussion).

Activation of STAT3 but Not STAT5 by Fes in Sf-9 Insect Cells-- Experiments conducted in 293T cells clearly demonstrate the ability of Fes to induce STAT3 DNA binding activity (Fig. 1). One possible mechanism of activation involves direct phosphorylation of STAT3 by Fes, leading to dimerization and DNA binding. Alternatively, it is possible that Fes may mediate its effects on STAT3 indirectly by activating endogenous JAKs or other tyrosine kinases, which in turn mediate STAT activation. The latter mechanism may contribute to STAT activation by both v-Abl and v-Src (8, 9). To address the issue of STAT activation by Fes more directly, we utilized the baculovirus/Sf-9 cell system to circumvent the issue of endogenous mammalian tyrosine kinases. For these experiments, Sf-9 insect cells were infected with a recombinant STAT3 baculovirus either alone or in combination with wild-type or kinase-inactive Fes baculoviruses. Cytosolic extracts were examined for the presence of activated STAT3 by gel-shift assay with the SIE probe. As shown in Fig. 4, co-expression with Fes induced potent activation of STAT3 in Sf-9 cells, consistent with the result observed in 293T cells (Fig. 1). The Fes-induced SIE·STAT3 complex was fully competed with a 100-fold excess of unlabeled SIE, indicative of binding specificity. In contrast, the kinase-inactive mutant of Fes produced no detectable increase in STAT3 activation above background. These results strongly suggest that Fes is capable of directly activating STAT3 without the requirement for a member of the JAK family or another intermediate tyrosine kinase.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 4.   Activation of STAT3 by Fes in Sf-9 cells. STAT3, STAT5, Fes, or a kinase-inactive Fes mutant (Fes-KE) were expressed in Sf-9 insect cells either alone or in the combinations shown. Cytosolic extracts were prepared and tested for the presence of active STAT3 by gel-shift analysis with an SIE probe. Control lanes include incubation of the probe in the absence of extract (SIE) and gel-shift assays of extracts from cells infected with a wild-type baculovirus (AcMNPV). Duplicate gel-shift assays were conducted in the presence of a 100-fold excess of unlabeled SIE to demonstrate probe specificity (COMP). The shifted complex of activated STAT3 and the SIE probe is denoted by the arrow.

The effect of Fes on STAT5 activation was also investigated in Sf-9 insect cells using the gel-shift assay and MGFE probe. As shown in Fig. 5, no detectable STAT5 DNA binding activity was observed in the presence of Fes. This result is in contrast to the tyrosine phosphorylation and activation of STAT5 by Fes observed in 293T cells (Figs. 2 and 3). Taken together, these results suggest that activation of STAT5 by Fes in 293T cells is indirect, possibly involving activation of an endogenous tyrosine kinase by Fes which in turn activates STAT5.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 5.   Co-expression with Fes fails to activate STAT5 in Sf-9 cells. STAT3, STAT5, Fes, or a kinase-inactive Fes mutant (Fes-KE) were expressed in Sf-9 insect cells either alone or in the combinations shown. Cytosolic extracts were prepared and tested for the presence of active STAT5 by gel-shift analysis with an MGFE probe. Control lanes include incubation of the probe in the absence of extract (MGFE) and gel-shift assays of extracts from cells infected with a wild-type baculovirus (AcMNPV). Duplicate gel-shift assays were conducted in the presence of a 100-fold excess of unlabeled SIE to demonstrate probe specificity (COMP). Note that activated STAT3 (Fes + STAT3) does not produce a gel-shift with the MGFE, indicative of probe specificity.

To control for the expression of Fes and STAT proteins in the Sf-9 cell experiments, immunoblots were performed on the cell extracts used for the gel-shift assays. As shown in Fig. 6, Fes and STAT proteins were all strongly expressed in the infected cells. In addition, immunoblots of the same extracts with an anti-phosphotyrosine antibody revealed potent tyrosine phosphorylation of STAT3 in the presence of Fes, consistent with the strong signal observed in the gel-shift assay (Fig. 4). Also visible in this experiment is autophosphorylated Fes. On the other hand, no tyrosine phosphorylation of STAT5 was detected, despite the presence of active Fes. This result is consistent with the negative gel-shift result with extracts from cells co-infected with Fes and STAT5 (Fig. 5).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 6.   Fes phosphorylates STAT3 but not STAT5 in Sf-9 cells. Immunoblots were performed on the cytosolic extracts from the Sf-9 insect cells infected with the Fes and STAT baculoviruses used for the gel-shift assays shown in Figs. 4 and 5. The anti-phosphotyrosine antibody, PY20, detects Fes autophosphorylation (upper arrow, top panel) and tyrosine phosphorylation of STAT3 when co-expressed with Fes (lower arrow, top panel). Immunoblots performed with antibodies against Fes, STAT3, and STAT5 confirm the expression of these proteins (bottom three panels).

An alternative explanation for the negative gel-shift result with Fes and STAT5 in Sf-9 cells is that the baculovirus-expressed STAT5 protein may be resistant to activation in the insect cell context. To rule out this possibility, STAT5 was co-expressed with the p210 form of Bcr-Abl, the constitutively activated protein-tyrosine kinase associated with chronic myelogenous leukemia (33). Several recent reports have shown that Bcr-Abl induces the activation of STAT5 as well as STATs 1 and 3 (10-12). Using the gel-shift assay with the MGFE probe, we observed that STAT5 was readily activated by Bcr-Abl in Sf-9 cells, whereas no detectable activation occurred with Fes (Fig. 7). This result indicates that baculovirus-expressed STAT5 can bind to DNA following phosphorylation by the appropriate tyrosine kinase. We also observed potent activation of STAT3 by Bcr-Abl in Sf-9 cells (Fig. 7). Our observation of Bcr-Abl-induced STAT activation in Sf-9 cells is consistent with previous work by Ilaria and Van Etten (12), which suggests that STATs are directly activated by Bcr-Abl and do not require JAKs or other endogenous kinases.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 7.   Activation of STAT3 and STAT5 by Bcr-Abl in Sf-9 insect cells. STAT3, STAT5, Fes or the p210 form of Bcr-Abl were expressed in Sf-9 insect cells either alone or in the combinations shown. Cytosolic extracts were prepared and tested for the presence of active STAT3 (top) or STAT5 (bottom) by gel-shift analysis with the SIE or MGFE probes, respectively. Duplicate gel-shift assays were conducted in the presence of a 100-fold excess of unlabeled probe to demonstrate probe specificity (COMP).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Data presented in this report demonstrate for the first time that STAT3 can be activated by the c-Fes tyrosine kinase. Our approach was to compare STAT activation in human versus insect cell backgrounds to address the issue of whether endogenous mammalian tyrosine kinases play a role in the activation mechanism. Our observations that Fes strongly activates STAT3 in both human and insect cells suggest that Fes is sufficient to activate STAT3 without a requirement for JAKs or other tyrosine kinase intermediates. However, the possible contribution of other tyrosine kinases to the activation mechanism in mammalian cells cannot be formally ruled out. These findings with STAT3 are consistent with our recent work showing that endogenous STAT3 activation occurs in fibroblasts transformed by v-Fps, the retroviral homolog of c-Fes (13). Taken together, these data suggest that v-Fps may directly induce endogenous STAT3 activation as well. In contrast to STAT3, however, we observed that Fes was unable to activate STAT5 in insect cells, despite some degree of activation in mammalian cells. These findings suggest that Fes activates STAT5 via an indirect mechanism, possibly via endogenous tyrosine kinases. Such a phenomenon has been reported previously for the activation of STATs by both v-Abl and Src kinases (8, 9).

Potent activation of STAT3 by Fes in transfected human cells suggests that such an event may also be induced by Fes in hematopoietic cells, an important site of Fes expression (14-16). Fes has been linked to the induction of myeloid differentiation in both normal and leukemic cell lines (21, 22, 34). Two recent studies have strongly implicated STAT3 as a key component of myeloid differentiation as well. Both of these studies utilized dominant-negative mutants of STAT3 (23, 24). These mutants were produced by substitution of the STAT3 tyrosine phosphorylation site with phenylalanine or by mutation of residues critical for DNA binding. When these mutants were introduced into M1 myeloid leukemia cells, the cells no longer responded to IL-6 with growth arrest and terminal differentiation. Interestingly, IL-6 is one of the cytokines reported to activate Fes (19). Taken together, these results suggest that Fes may contribute to the IL-6-mediated activation of STAT3 and the subsequent differentiation response.

Recent studies of GM-CSF-treated neutrophils also suggest a connection between Fes and STAT3 activation (35). In these experiments, GM-CSF was shown to induce the formation of a multiprotein complex consisting of Fes, JAK2, STAT1, STAT3, and the beta -subunit of the GM-CSF receptor. However, this previous study did not address the possible contribution of Fes to STAT activation. Data presented here clearly demonstrate the tyrosine phosphorylation of STAT3 by Fes and induction of its DNA binding activity, strongly suggesting that this activation mechanism may be direct. The GM-CSF receptor may serve as a docking site to bring Fes and STAT3 into close proximity to allow the phosphorylation event to occur. Such an interaction may be initiated by JAK2, which could create binding sites for the SH2 domains of Fes and STAT3 on the receptor beta -subunit. Further experiments will be required to address the possible contribution of Fes to STAT activation in response to cytokine treatment. However, a definitive demonstration that Fes is involved in endogenous STAT3 activation by GM-CSF, IL-6, or other cytokines may be difficult because of the multiple non-receptor tyrosine kinases activated in response to cytokine treatment.

Although our results in Sf-9 insect cells indicate that STAT5 is not a direct substrate for Fes, co-expression of these two proteins in human cells induced both STAT5 tyrosine phosphorylation and DNA binding activity. These results suggest that Fes may indirectly induce STAT5 activation under physiological conditions. Like STAT3, STAT5 may also contribute to hematopoietic differentiation in some cases. Recent studies have established a strong correlation between STAT5 activation and differentiation of myeloid leukemia cell lines (36). In these experiments, induction of monocytic differentiation in human U937 cells with phorbol ester, retinoic acid, or 1alpha ,25-dihydroxy-vitamin D3 induced strong DNA binding activity of STAT5. Similar results were observed following chemically induced differentiation of HL-60 promyelocytic leukemia cells. In the same study, STAT5 activation was observed in primary cultures of chicken myeloblasts following differentiation to macrophages with chicken myelomonocytic growth factor. Another recent study has shown that induction of megakaryocytic differentiation by thrombopoietin correlates with activation of STAT5. This study also identified the cyclin-dependent kinase inhibitor p21WAF1/Cip1 as a possible target gene for STAT5 in the differentiation response (37). Further work will be required to determine whether Fes can stimulate similar STAT5 responses as part of a differentiation signaling pathway in hematopoietic cells.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant CA58667, American Cancer Society Research Grant BE-245, and National Cancer Institute Cancer Center Support Grant P30 CA36727 to the Eppley Institute for Research in Cancer.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Eppley Institute for Research in Cancer, University of Nebraska Medical Center, 600 S. 42nd St., Omaha, NE 68198-6805. Tel.: 402-559-8270; Fax: 402-559-4651; E-mail: tsmithga{at}unmc.edu.

1 The abbreviations used are: TBST, Tris-buffered saline containing 0.05% Tween-20; SIE, sis-inducible element; MGFE, mammary gland factor element.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Ihle, J. N., Witthuhn, B. A., Quelle, F. W., Yamamoto, K., Silvennoinen, O. (1995) Annu. Rev. Immunol. 13, 369-398[CrossRef][Medline] [Order article via Infotrieve]
  2. Schindler, C., and Darnell, J. E., Jr. (1995) Annu. Rev. Biochem. 64, 621-651[CrossRef][Medline] [Order article via Infotrieve]
  3. Ihle, J. N. (1996) Cell 84, 331-334[Medline] [Order article via Infotrieve]
  4. Watanabe, S., and Arai, K. (1996) Curr. Opin. Genet. Dev. 6, 587-596[CrossRef][Medline] [Order article via Infotrieve]
  5. Darnell, J. E., Jr. (1997) Science 277, 1630-1635[Abstract/Free Full Text]
  6. Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., Jove, R. (1995) Science 269, 81-83[Medline] [Order article via Infotrieve]
  7. Cao, X. M., Tay, A., Guy, G. R., Tan, Y. H. (1996) Mol. Cell. Biol. 16, 1595-1603[Abstract]
  8. Campbell, G. S., Yu, C.-L., Jove, R., and Carter-Su, C. (1997) J. Biol. Chem. 272, 2591-2594[Abstract/Free Full Text]
  9. Danial, N. N., Pernis, A., and Rothman, P. B. (1995) Science 269, 1875-1877[Medline] [Order article via Infotrieve]
  10. Shuai, K., Halpern, J., ten Hoeve, J., Rao, X. P., Sawyers, C. L. (1996) Oncogene 13, 247-254[Medline] [Order article via Infotrieve]
  11. Carlesso, N., Frank, D. A., and Griffin, J. D. (1996) J. Exp. Med. 183, 811-820[Abstract]
  12. Ilaria, R. L., Jr., and Van Etten, R. A. (1996) J. Biol. Chem. 271, 31704-31710[Abstract/Free Full Text]
  13. Garcia, R., Yu, C.-L., Hudnall, A., Catlett, R., Nelson, K., Smithgall, T. E., Fujita, D. J., Ethier, S., Jove, R. (1998) Cell Growth Differ. 8, 1267-1276[Abstract]
  14. Smithgall, T. E., Yu, G., and Glazer, R. I. (1988) J. Biol. Chem. 263, 15050-15055[Abstract/Free Full Text]
  15. Feldman, R. A., Gabrilove, J. L., Tam, J. P., Moore, M. A. S., Hanafusa, H. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 2379-2383[Abstract]
  16. MacDonald, I., Levy, J., and Pawson, T. (1985) Mol. Cell. Biol. 5, 2543-2551[Medline] [Order article via Infotrieve]
  17. Hanazono, Y., Chiba, S., Sasaki, K., Mano, H., Yazaki, Y., and Hirai, H. (1993) Blood 81, 3193-3196[Abstract]
  18. Hanazono, Y., Chiba, S., Sasaki, K., Mano, H., Miyajima, A., Arai, K., Yazaki, Y., and Hirai, H. (1993) EMBO J. 12, 1641-1646[Abstract]
  19. Matsuda, T., Fukada, T., Takahashi-Tezuka, M., Okuyama, Y., Fujitani, Y., Hanazono, Y., Hirai, H., and Hirano, T. (1995) J. Biol. Chem. 270, 11037-11039[Abstract/Free Full Text]
  20. Izuhara, K., Feldman, R. A., Greer, P., and Harada, N. (1994) J. Biol. Chem. 269, 18623-18629[Abstract/Free Full Text]
  21. Yu, G., Smithgall, T. E., and Glazer, R. I. (1989) J. Biol. Chem. 264, 10276-10281[Abstract/Free Full Text]
  22. Carmier, J. F., and Samarut, J. (1986) Cell 44, 159-165[Medline] [Order article via Infotrieve]
  23. Nakajima, K., Yamanaka, Y., Nakae, K., Kojima, H., Ichiba, M., Kiuchi, N., Kitaoka, T., Fukada, T., Hibi, M., and Hirano, T. (1996) EMBO J. 15, 3651-3658[Abstract]
  24. Minami, M., Inoue, M., Wei, S., Takeda, K., Matsumoto, M., Kishimoto, T., and Akira, S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3963-3966[Abstract/Free Full Text]
  25. Pear, W. S., Nolan, G. P., Scott, M. L., Baltimore, D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8392-8396[Abstract/Free Full Text]
  26. Rogers, J. A., Read, R. D., Li, J., Peters, K. L., Smithgall, T. E. (1996) J. Biol. Chem. 271, 17519-17525[Abstract/Free Full Text]
  27. Pallard, C., Gouilleux, F., Charon, M., Groner, B., Gisselbrecht, S., and Dusanter-Fourt, I. (1995) J. Biol. Chem. 270, 15942-15945[Abstract/Free Full Text]
  28. Nelson, K. L., Becker, N. A., Pahwa, G. S., Hollingsworth, M. A., Maher, L. J., III (1996) J. Biol. Chem. 271, 18061-18067[Abstract/Free Full Text]
  29. Yamanaka, Y., Nakajima, K., Fukada, T., Hibi, M., and Hirano, T. (1996) EMBO J. 15, 1557-1565[Abstract]
  30. Hjermstad, S., Peters, K. L., Briggs, S. D., Glazer, R. I., Smithgall, T. E. (1993) Oncogene 8, 2283-2292[Medline] [Order article via Infotrieve]
  31. Maru, Y., Peters, K. L., Afar, D. E. H., Shibuya, M., Witte, O. N., Smithgall, T. E. (1995) Mol. Cell. Biol. 15, 835-842[Abstract]
  32. Li, J., and Smithgall, T. E. (1996) J. Biol. Chem. 271, 32930-32936[Abstract/Free Full Text]
  33. Sawyers, C. L. (1992) Cancer Surv. 15, 37-51[Medline] [Order article via Infotrieve]
  34. Manfredini, R., Grande, A., Tagliafico, E., Barbieri, D., Zucchini, P., Citro, G., Zupi, G., Franceschi, C., Torelli, U., and Ferrari, S. (1993) J. Exp. Med. 178, 381-389[Abstract]
  35. Brizzi, M. F., Aronica, M. G., Rosso, A., Bagnara, G. P., Yarden, Y., Pegoraro, L. (1996) J. Biol. Chem. 271, 3562-3567[Abstract/Free Full Text]
  36. Woldman, I., Mellitzer, G., Kieslinger, M., Buchhart, D., Meinke, A., Beug, H., and Decker, T. (1997) J. Immunol. 159, 877-886[Abstract]
  37. Matsumura, I., Ishikawa, J., Nakajima, K., Oritani, K., Tomiyama, Y., Miyagawa, J. I., Kato, T., Miyazaki, H., Matsuzawa, Y., Kanakura, Y. (1997) Mol. Cell. Biol. 17, 2933-2943[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.